Intalere Members Benefit through New Agreement with Fosun Pharma USA
St. Louis (April 29, 2020) – Intalere, the healthcare industry leader in delivering solutions designed for improved financial, operational and clinical health for our partners, announces a new agreement for injectable pharmaceuticals from Fosun Pharma USA.
Through this agreement Intalere members will receive negotiated pricing on Fosun Pharma USA specialty pharmaceutical injectables in many therapeutic areas, including anti-emetic, anti-infective, anti-inflammatory, cardiovascular and oncology.
This contract is currently effective through January 31, 2025.
About Fosun Pharma USA
Fosun Pharma USA was founded in 2017 and continually works to enhance our existing portfolio of specialty pharmaceutical injectables and to build our pipeline with both innovative and generic pharmaceutical drugs. With strategic manufacturing partnerships around the world, Fosun Pharma USA delivers high-quality products that comply with international standards. For more information, visit www.fosunpharmausa.com.
Intalere’s mission focuses on elevating the health of healthcare by designing solutions to improve our members’ financial, operational and clinical performance. We empower our customers and deliver measurable results through our highly personalized approach of creating strategies and programs focused on their goals. From managing their entire spend to strategic consulting around diagnosing particular areas of concern, our unique provider led model allows us to leverage nationally recognized best practices in supply chain and patient outcomes to drive efficiencies for our members. To learn more, visit www.intalere.com.